# EDGAR Filing Document

**Accession Number:** 0001806952
**File Stem:** 0001193125-25-166426
**Filing Date:** 2025-7
**Character Count:** 2176
**Document Hash:** ef3c9913bba6591a40efc9b4a0e1806c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-166426.hdr.sgml**: 20250827

**ACCESSION NUMBER**: 0001193125-25-166426

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250728

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lyell Immunopharma, Inc.
- **CENTRAL INDEX KEY:** 0001806952
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 833006753
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 201 HASKINS WAY
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 650 695-0677

**MAIL ADDRESS:**
- **STREET 1:** 201 HASKINS WAY
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**LYELL IMMUNOPHARMA, INC.** 

201 Haskins Way

South San Francisco, California 94080

(650) 695-0677

July 28, 2025

**<u>VIA EDGAR</u>**

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, NE

Washington, D.C. 20549

Attn: Alan Campbell

---

| | |
|:---|:---|
| *RE:* | Lyell Immunopharma, Inc*.* (the "***Company***")  |

---

Registration Statement on Form S-3

File No. 333-288769

Dear Mr. Campbell:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby respectfully requests that the effective date of the Company's Registration Statement on Form S-3 (File No. 333-288769) be accelerated by the Securities and Exchange Commission to 4:00 p.m. New York time on July 30, 2025, or as soon as practicable thereafter.

We request that we be notified of such effectiveness by a telephone call to Thomas W. Greenberg of Skadden, Arps, Slate, Meagher & Flom LLP at (212) 735-7886 and that such effectiveness also be confirmed in writing.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| Lyell Immunopharma, Inc. | Lyell Immunopharma, Inc. |
| By: | /s/ Mark Meltz |
|  | Mark Meltz |
|  | General Counsel and Corporate Secretary |

---

cc: Thomas W. Greenberg

*Skadden, Arps, Slate, Meagher & Flom LLP*